Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for CytomX Therapeutics (CTMX) over the last 9 years, with Q3 2025 value amounting to $4.3 million.

  • CytomX Therapeutics' Other Non-Current Liabilities rose 606.96% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 606.96%. This contributed to the annual value of $4.1 million for FY2024, which is 570.25% up from last year.
  • As of Q3 2025, CytomX Therapeutics' Other Non-Current Liabilities stood at $4.3 million, which was up 606.96% from $4.2 million recorded in Q2 2025.
  • CytomX Therapeutics' 5-year Other Non-Current Liabilities high stood at $4.3 million for Q3 2025, and its period low was $216000.0 during Q2 2023.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $4.0 million (2024), whereas its average is $3.6 million.
  • Examining YoY changes over the last 5 years, CytomX Therapeutics' Other Non-Current Liabilities showed a top increase of 174861.11% in 2024 and a maximum decrease of 570.25% in 2024.
  • Over the past 3 years, CytomX Therapeutics' Other Non-Current Liabilities (Quarter) stood at $3.9 million in 2023, then rose by 5.7% to $4.1 million in 2024, then grew by 4.47% to $4.3 million in 2025.
  • Its last three reported values are $4.3 million in Q3 2025, $4.2 million for Q2 2025, and $4.2 million during Q1 2025.